329 related articles for article (PubMed ID: 23406560)
1. Targeting RANKL in breast cancer: bone metastasis and beyond.
Azim H; Azim HA
Expert Rev Anticancer Ther; 2013 Feb; 13(2):195-201. PubMed ID: 23406560
[TBL] [Abstract][Full Text] [Related]
2. [Involvement of RANKL/RANK pathway in bone metastasis in breast cancer].
Yoneda T
Clin Calcium; 2011 Aug; 21(8):1159-66. PubMed ID: 21814020
[TBL] [Abstract][Full Text] [Related]
3. [Anti-RANKL antibody for treatment of patients with bone metastasis from breast cancer].
Takahashi S
Gan To Kagaku Ryoho; 2012 Jan; 39(1):89-94. PubMed ID: 22241358
[TBL] [Abstract][Full Text] [Related]
4. Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis.
Lipton A; Goessl C
Bone; 2011 Jan; 48(1):96-9. PubMed ID: 20950721
[TBL] [Abstract][Full Text] [Related]
5. Denosumab for the treatment of bone metastases in advanced breast cancer.
Casas A; Llombart A; Martín M
Breast; 2013 Oct; 22(5):585-92. PubMed ID: 23759273
[TBL] [Abstract][Full Text] [Related]
6. [Therapeutic agents for disorders of bone and calcium metabolism--Denosumab, a fully human monoclocal antibody-targeting RANKL as a therapy for cancer-induced bone diseases].
Mera K; Ito K
Clin Calcium; 2007 Jan; 17(1):37-46. PubMed ID: 17211092
[TBL] [Abstract][Full Text] [Related]
7. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.
Dougall WC
Clin Cancer Res; 2012 Jan; 18(2):326-35. PubMed ID: 22031096
[TBL] [Abstract][Full Text] [Related]
8. Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors.
Lipton A; Balakumaran A
Expert Rev Clin Pharmacol; 2012 Jul; 5(4):359-71. PubMed ID: 22943116
[TBL] [Abstract][Full Text] [Related]
9. The RANK/RANKL/OPG triad in cancer-induced bone diseases.
Dougall WC; Chaisson M
Cancer Metastasis Rev; 2006 Dec; 25(4):541-9. PubMed ID: 17180711
[TBL] [Abstract][Full Text] [Related]
10. Denosumab for treatment of breast cancer bone metastases and beyond.
Nangia JR; Ma JD; Nguyen CM; Mendes MA; Trivedi MV
Expert Opin Biol Ther; 2012 Apr; 12(4):491-501. PubMed ID: 22348344
[TBL] [Abstract][Full Text] [Related]
11. RANKL inhibition in the treatment of bone metastases.
Lipton A; Jun S
Curr Opin Support Palliat Care; 2008 Sep; 2(3):197-203. PubMed ID: 18685421
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of bone metastasis by denosumab, the human monoclonal neutralizing antibody to RANKL].
Yoneda T
Nihon Rinsho; 2012 Dec; 70(12):2165-71. PubMed ID: 23259391
[TBL] [Abstract][Full Text] [Related]
13. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
Canon J; Bryant R; Roudier M; Branstetter DG; Dougall WC
Breast Cancer Res Treat; 2012 Oct; 135(3):771-80. PubMed ID: 22926264
[TBL] [Abstract][Full Text] [Related]
14. The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review.
de Groot AF; Appelman-Dijkstra NM; van der Burg SH; Kroep JR
Cancer Treat Rev; 2018 Jan; 62():18-28. PubMed ID: 29154022
[TBL] [Abstract][Full Text] [Related]
15. Denosumab in breast cancer treatment.
Drooger JC; van der Padt A; Sleijfer S; Jager A
Eur J Pharmacol; 2013 Oct; 717(1-3):12-9. PubMed ID: 23545361
[TBL] [Abstract][Full Text] [Related]
16. [Anti-RANKL antibody for the management of bone metastasis].
Yoneda T
Gan To Kagaku Ryoho; 2011 Sep; 38(9):1439-45. PubMed ID: 21918338
[TBL] [Abstract][Full Text] [Related]
17. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
18. Denosumab: benefits of RANK ligand inhibition in cancer patients.
Lipton A; Jacobs I
Curr Opin Support Palliat Care; 2011 Sep; 5(3):258-64. PubMed ID: 21826000
[TBL] [Abstract][Full Text] [Related]
19. Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastases.
Saad F; Markus R; Goessl C
BJU Int; 2008 May; 101(9):1071-5. PubMed ID: 18070191
[TBL] [Abstract][Full Text] [Related]
20. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.
Body JJ; Facon T; Coleman RE; Lipton A; Geurs F; Fan M; Holloway D; Peterson MC; Bekker PJ
Clin Cancer Res; 2006 Feb; 12(4):1221-8. PubMed ID: 16489077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]